Human prion protein-mediated calcineurin activation induces neuron cell death via AMPK and autophagy pathway

• Published in: The international journal of biochemistry & cell biology 2020-02, Vol.119, p.105680, Article 105680
• Main Authors: Hong, Jeong-Min, Moon, Ji-Hong, Park, Sang-Youel
• Format: Article
• Language: English
• Subjects: AMP-Activated Protein Kinases - metabolism; AMPK; Apoptosis - drug effects; Autophagy; Autophagy - drug effects; Calcineurin; Calcineurin - metabolism; Calcineurin Inhibitors - pharmacology; Cell Line, Tumor; Humans; Neuroblastoma - drug therapy; Neuroblastoma - enzymology; Neuroblastoma - metabolism; Neuroblastoma - pathology; Neurons - drug effects; Neurons - enzymology; Neurons - metabolism; Neurons - pathology; Neurotoxicity; Peptide Fragments - pharmacology; Phosphorylation - drug effects; Prion; Prions - pharmacology; Tacrolimus - pharmacology
• ISSN: 1357-2725; 1878-5875
• DOI: 10.1016/j.biocel.2019.105680

It is usually accepted that prion proteins induce apoptosis in nerve cells. However, the mechanisms of PrPSc-neurotoxicity are not completely clear. Calcineurin is a Ca2+/calmodulin-dependent phosphatase. It activates autophagy, and may represent a link between deregulation of Ca2+ homeostasis and neuronal cell death. In this study, the effect of calcineurin activation mediated by human prion protein induced neuronal cell death via AMPK dephosphorylation and autophagy, was investigated. Synthetic peptides of PrP (PrP 106–126) increased calcineurin activity, without changing the levels of this protein phosphatase. Furthermore, these peptides reduced the levels of AMPK phosphorylation at threonine residue 172 and in autophagy activation. Calcineurin inhibitor, FK506, prevented this effect. The data showed that PrP-treated neurons had lower levels of AMPK than control neurons. This decrease in AMPK levels was matched via activation of autophagy. FK506 prevented the changes in AMPK and autophagy levels induced by PrP peptides. Taken together, the data demonstrated that prion peptides triggered an apoptotic cascade via calcineurin activation, which mediated AMPK dephosphorylation and autophagy activation. Therefore, these data suggest that therapeutic strategies targeting calcineurin inhibition might facilitate the management of neurodegenerative disorders including prion disease.